Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

  • Chaib, Imane
  • Karachaliou, Niki
  • Pilotto, Sara
  • Codony-Servat, Jordi
  • Cai, Xueting
  • Li, Xuefei
  • Drozdowskyj, Ana
  • Codony Servat, Carles|||0000-0001-8928-2312
  • Yang, Jie
  • Hu, Chunping
  • Cardona Zorrilla, Andrés Felipe|||0000-0003-3525-4126
  • Lopez Vivanco, Guillermo
  • Vergnenegre, Alain
  • Sánchez Torres, José Miguel
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Marinis, Filippo de
  • Passaro, Antonio|||0000-0002-7575-3870
  • Carcereny, Enric|||0000-0001-5235-5602
  • Reguart, Noemi|||0000-0001-8190-499X
  • Garcia Campelo, Charo
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Sperduti, Isabella
  • Rodriguez, Sonia
  • Lavazzi, Chiara
  • Verlicchi, Alberto
  • Aguirre, Itziar de
  • Queralt, C.|||0000-0001-9875-0173
  • Wei, Jia|||0000-0001-9621-529X
  • Estrada-Tejedor, Roger|||0000-0002-2983-0492
  • Puig de la Bellacasa, Raimon|||0000-0001-8349-4082
  • Ramirez, Jose Luis
  • Jacobson, Kirstine
  • Ditzel, Henrik J.
  • Santarpia, Mariacarmela
  • Viteri, Santiago|||0000-0002-7572-1123
  • Molina, Miguel Angel
  • Zhou, Caicun
  • Cao, Peng
  • Ma, Patrick C.
  • Bivona, Trever
  • Rosell, Rafael|||0000-0003-0817-3400
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals.We hypothesized that both signal transducer and activator of transcription 3 (STAT3) and Src-YES-associated protein 1 (YAP1) signaling are dually activated during EGFR TKI treatment to limit therapeutic response. Methods: We used MTT and clonogenic assays, immunoblotting, and quantitative polymerase chain reaction to evaluate the efficacy of EGFR TKI alone and in combination with STAT3 and Src inhibition in three EGFR-mutant NSCLC cell lines. The Chou-Talalay method was used for the quantitative determination of drug interaction. We examined tumor growth inhibition in one EGFR-mutant NSCLC xenograft model (n¼4 mice per group). STAT3 and YAP1 expression was evaluated in tumors from 119 EGFR-mutant NSCLC patients (64 in an initial cohort and 55 in a validation cohort) by quantitative polymerase chain reaction. Kaplan-Meier and Cox regression analyses were used to assess the correlation between survival and gene expression. All statistical tests were two-sided. Results: We discovered that lung cancer cells survive initial EGFR inhibitor treatment through activation of not only STAT3 but also Src-YAP1 signaling. Cotargeting EGFR, STAT3, and Src was synergistic in two EGFR-mutant NSCLC cell lines with a combination index of 0.59 (95% confidence interval [CI] ¼ 0.54 to 0.63) for the PC-9 and 0.59 (95% CI¼0.54 to 0.63) for the H1975 cell line. High expression of STAT3 or YAP1 predicted worse progression-free survival (hazard ratio [HR] ¼ 3.02, 95% CI¼1.54 to 5.93, P ¼ .001, and HR¼2.57, 95% CI¼1.30 to 5.09, P ¼ .007, respectively) in an initial cohort of 64 EGFR-mutant NSCLC patients treated with firstline EGFR TKIs. Similar results were observed in a validation cohort. Conclusions: Our study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.